Shijiazhuang Yiling Pharmaceutical Co Ltd - Asset Resilience Ratio
Shijiazhuang Yiling Pharmaceutical Co Ltd (002603) has an Asset Resilience Ratio of 6.40% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read 002603 total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2023)
This chart shows how Shijiazhuang Yiling Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. See Shijiazhuang Yiling Pharmaceutical Co Lt (002603) shareholders funds for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Shijiazhuang Yiling Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 002603 company net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥910.50 Million | 6.4% |
| Total Liquid Assets | CN¥910.50 Million | 6.40% |
Asset Resilience Insights
- Limited Liquidity: Shijiazhuang Yiling Pharmaceutical Co Ltd maintains only 6.40% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Shijiazhuang Yiling Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio
Compare Shijiazhuang Yiling Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Daihan Pharmaceutical Co.Ltd
KQ:023910 |
Drug Manufacturers - Specialty & Generic | 11.95% |
|
Aurobindo Pharma Limited
NSE:AUROPHARMA |
Drug Manufacturers - Specialty & Generic | 16.92% |
|
China Resources Sanjiu Medical & Pharmaceutical Co Ltd
SHE:000999 |
Drug Manufacturers - Specialty & Generic | 5.22% |
|
Ningbo Menovo Pharm Co Ltd
SHG:603538 |
Drug Manufacturers - Specialty & Generic | 2.69% |
|
Zhejiang Xianju Pharmaceutical Co Ltd
SHE:002332 |
Drug Manufacturers - Specialty & Generic | 6.02% |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365 |
Drug Manufacturers - Specialty & Generic | 30.38% |
|
Hainan Honz Pharmaceutical Co
SHE:300086 |
Drug Manufacturers - Specialty & Generic | 0.27% |
|
Guangdong Lifestrong Pharmacy Co. Ltd.
SHE:301111 |
Drug Manufacturers - Specialty & Generic | 7.85% |
Annual Asset Resilience Ratio for Shijiazhuang Yiling Pharmaceutical Co Ltd (2014–2023)
The table below shows the annual Asset Resilience Ratio data for Shijiazhuang Yiling Pharmaceutical Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 1.21% | CN¥205.97 Million ≈ $30.14 Million |
CN¥16.98 Billion ≈ $2.48 Billion |
-1.96pp |
| 2022-12-31 | 3.17% | CN¥518.38 Million ≈ $75.86 Million |
CN¥16.34 Billion ≈ $2.39 Billion |
+2.74pp |
| 2021-12-31 | 0.43% | CN¥55.27 Million ≈ $8.09 Million |
CN¥12.90 Billion ≈ $1.89 Billion |
-1.46pp |
| 2020-12-31 | 1.89% | CN¥216.97 Million ≈ $31.75 Million |
CN¥11.49 Billion ≈ $1.68 Billion |
-1.34pp |
| 2019-12-31 | 3.23% | CN¥292.73 Million ≈ $42.84 Million |
CN¥9.07 Billion ≈ $1.33 Billion |
-0.88pp |
| 2018-12-31 | 4.11% | CN¥351.76 Million ≈ $51.47 Million |
CN¥8.56 Billion ≈ $1.25 Billion |
-6.84pp |
| 2017-12-31 | 10.95% | CN¥863.39 Million ≈ $126.34 Million |
CN¥7.89 Billion ≈ $1.15 Billion |
+9.77pp |
| 2014-12-31 | 1.18% | CN¥60.00 Million ≈ $8.78 Million |
CN¥5.09 Billion ≈ $744.52 Million |
-- |
About Shijiazhuang Yiling Pharmaceutical Co Ltd
Shijiazhuang Yiling Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of Chinese medicine primarily in China. It offers drugs for cardiovascular and cerebrovascular, respiratory, endocrine, neurological, digestive, immune, and urinary diseases, diabetes mellitus, oncology, sleep-improving, and anti-aging. The company also provides dietary supplements, disinfec… Read more